Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta
Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta
PR Newswire
BUENOS AIRES, Argentina, Aug. 26, 2026
BUENOS AIRES, Argentina, Aug. 26, 2026 /PRNewswire/ -- Biosidus, an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company's biologics production capacity and reinforcing its ability to support potential international demand.
The expansion strengthens Biosidus' industrial platform at a time when healthcare systems are placing increasing emphasis on manufacturing reliability, continuity of treatment and diversified sources of complex biologic medicines.
Developed and manufactured in Argentina, Biosidus' agalsidase beta, its biosimilar enzyme replacement therapy for Fabry disease, represents a significant milestone in the company's biotechnology platform and its growing focus on treatments for rare diseases.
With additional production capacity, Biosidus is strengthening its international supply capabilities and is prepared to engage with partners and health authorities evaluating sustainable and reliable sources of agalsidase beta supply.
"Continuity of treatment is particularly critical for patients living with rare and chronic diseases. Expanding our productive capacity reinforces our commitment to making Biosidus' biotechnology capabilities available to healthcare systems seeking sustainable and reliable access to high-quality biologic medicines," said Mario Koch, Director of Rare Diseases.
After launching agalsidase beta in Argentina in 2025, Biosidus is advancing the international expansion of its program and is available to evaluate extraordinary supply requirements in markets where the applicable regulatory pathways allow it.
The new bioreactor capacity is part of Biosidus' broader strategy of combining scientific capabilities, local manufacturing, industrial investment and international expansion to increase access to complex biologic therapies.
About Biosidus
Biosidus is an Argentine biotechnology company specializing in the development, manufacturing and commercialization of biosimilar medicines. With more than 40 years of experience in biotechnology and a presence in international markets, the company develops and manufactures complex biologic medicines across multiple therapeutic areas.
SOURCE Biosidus
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
The 10 Best Dividend Stocks
United States